[Brugada syndrome]

Area of Science:

• Cardiology
• Genetics
• Electrophysiology

Context:

• Brugada syndrome presents with characteristic electrocardiogram (ECG) abnormalities and risk of ventricular fibrillation in individuals without structural heart disease.
• The underlying cause is primarily attributed to genetic mutations affecting cardiac sodium channels (Na channelopathy).

Purpose:

• To elucidate the diagnostic criteria for Brugada syndrome, emphasizing the significance of Type 1 ECG morphology.
• To detail the diagnostic utility of sodium channel blockers, such as pilsicainide, in confirming Type 1 ECG patterns.
• To differentiate between Brugada syndrome and Brugada type ECG findings based on established European Society of Cardiology (ESC) guidelines.

Summary:

• Brugada syndrome diagnosis necessitates the presence of Type 1 ECG morphology, which can be confirmed using a sodium channel blocker challenge.
• The coved-type ECG (Type 1) is essential for diagnosis, though the saddle-back type (Types 2-3) is more common clinically and interchangeable.
• Patients meeting diagnostic criteria receive a Brugada syndrome diagnosis, while those with ECG findings alone are classified as having Brugada type ECG.

Impact:

• Definitive diagnosis guides risk stratification and management, with defibrillator implantation recommended for Brugada syndrome patients.
• Patients with Brugada type ECG, lacking definitive syndrome criteria, are managed with observation alone.
• Accurate diagnosis and classification are crucial for appropriate patient management and prevention of sudden cardiac death.